Teclistamab
- Generic Name
- Teclistamab
- Brand Names
- Tecvayli
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2119595-80-9
- Unique Ingredient Identifier
- 54534MX6Z9
- Background
Teclistamab is an IgG4-PAA bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and B cell maturation antigen (BCMA) expressed on malignant multiple myeloma cells. Teclistamab consists of an anti-BCMA arm and an anti-CD3 arm connected via two interchain disulfide bonds, allowing the drug to recruit CD3-expressing T cells to B...
- Indication
Teclistamab is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
...
- Associated Conditions
- Refractory Multiple Myeloma, Relapsed Multiple Myeloma
- Associated Therapies
- -
A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- European Myeloma Network B.V.
- Target Recruit Count
- 30
- Registration Number
- NCT06649695
- Locations
- 🇳🇱
UMC Utrecht, Utrecht, Netherlands
🇦🇺South Australia Health, Adelaide, Australia
🇦🇺Westmead Hospital, Sydney, Australia
ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 20
- Registration Number
- NCT06588660
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT06577025
- Locations
- 🇪🇸
Hosp Clinico Univ de Salamanca, Salamanca, Spain
🇪🇸Hosp. Univ. Marques de Valdecilla, Santander, Spain
🇺🇸City of Hope, Duarte, California, United States
Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- North Estonia Medical Centre
- Target Recruit Count
- 50
- Registration Number
- NCT06505369
- Locations
- 🇳🇴
Oslo University Hospital, Oslo Myeloma Centre, Oslo, Norway
🇳🇴Stavanger University Hospital, Stavanger, Norway
🇩🇰Vejle hospital, Vejle, Denmark
Study on the Clinical Efficacy of Teclistamab
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 100
- Registration Number
- NCT06477783
- Locations
- 🇧🇪
Jessa Ziekenhuis, Hasselt, Limburg, Belgium
🇧🇪CHU UCL Namur, Yvoir, Namur, Belgium
🇧🇪Algemeen Ziekenhuis Maria Middelares (AZMM), Gent, Oost-Vlaanderen, Belgium
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 26
- Registration Number
- NCT06465316
- Locations
- 🇺🇸
Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2024-05-23
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 100
- Registration Number
- NCT06425991
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇮🇱Carmel Medical Center, Haifa, Israel
🇮🇱Hadassah University Hospita Ein Kerem, Jerusalem, Israel
Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 103
- Registration Number
- NCT06353022
- Locations
- 🇫🇷
CHU Montpellier, Montpellier, France
🇫🇷CH Lyon Sud, Lyon, France
🇫🇷CH de la Côte Basque, Bayonne, France
Plan Development for Giving Teclistamab in the Outpatient Setting
- Conditions
- Interventions
- First Posted Date
- 2024-02-09
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 15
- Registration Number
- NCT06251076
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- Conditions
- Interventions
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 795
- Registration Number
- NCT06208150
- Locations
- 🇨🇳
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
🇨🇳Tongji Hospital, Tongji Medical College of HUST, Wuhan, China
🇮🇱Carmel Medical Center, Haifa, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.